Research on HIV epidemiology and control. Covers prevention policy, HIV-substance use links, TB co-treatment, and clearing infection in newborns.
The USF team, led by Dr. Jeffrey Nadler, is conducting a national study to assess the safety and ability of an HIV vaccine to stimulate immunity in healthy adults. The vaccine, developed by Merck & Co., uses a prime boost regimen and boosts the activity of killer cells in the immune system to target and kill HIV-infected cells.
The GlaxoSmithKline Drug Discovery and Development Award provides funding for innovative HIV/AIDS research, including therapies aimed at treating infection and preventing transmission. The award is intended to further the development of inventive treatments for HIV/AIDS.
Women in jail have high HIV infection rates, with specific risk factors identified as substance abuse disorders and severe mental illness. An HIV/AIDS education program in a correctional setting has shown promise in reducing the spread of HIV in communities.
According to a University of Pittsburgh study, HIV patients who underwent liver transplantation for hepatitis C virus did not experience further progression of their HIV despite taking immune-suppressing anti-rejection drugs. The study found that all six surviving patients had undetectable HIV viral loads since their transplants.
Researchers found that measles triggers intense immune system activation, temporarily suppressing HIV levels in children. The study suggests a potential clue to understanding HIV pathogenesis and immunity.
A study found that 43% of rural HIV-positive participants engage in elevated risk for transmitting their infection, often due to depression, stress, and lack of access to HIV-prevention programs. Many residents are isolated by the stigma of their illness and lack information about the dangers of unprotected sex.
A second-stage HIV vaccine trial has started in London and Oxford, recruiting 120 volunteers to assess the vaccine's safety and dosage. The trial aims to establish optimum vaccination schedules and booster injections to prevent HIV infection.
A study found that female injection drug users in Vancouver with high-risk behaviors like daily cocaine use and unsafe sex were more likely to convert to HIV. The authors emphasize the need for sex-specific prevention initiatives due to alarming rates of HIV infection among Aboriginal women, twice as high as in non-Aboriginal populations.
A UCLA study found that 75% of HIV-positive women reported a positive change in their views of themselves, while 53% reported a shift in life priorities. The women attributed this change to coping with HIV infection, which made them feel wiser and stronger.
A cross-sectional study of 493 married couples in Thailand found that HIV transmission from men to women is significantly linked to increased viral loads among HIV-positive men. Women who had previously contracted an STD or used hormonal contraceptives were also at higher risk of transmission.
A study found that genetic testing can identify HIV patients at risk of a life-threatening hypersensitive reaction to the antiretroviral drug abacavir. Patients with the HLA-B*5701 allele were over 100 times more likely to experience the adverse reaction.
The study found TMC125 effective against highly NNRTI-resistant HIV strains in patients failing treatment. The drug showed no signs of resistance development and was well-tolerated during the trial.
Researchers found that early in HIV infection, CD8 T cells become unresponsive to HIV surface molecules, suppressing their ability to attack infected cells. This leads to a dominant immunosuppressive response mediated by the molecule TGF-beta.
Researchers found that uncomplicated labor and vaginal delivery do not stimulate the babies' immune systems to HIV infection. Babies born to mothers with chorioamnionitis or preterm labor, however, showed activation of their white blood cells and higher risk of transmission.
Researchers have identified a cholesterol-depleting agent, beta-cyclodextrin, that blocks the transmission of cell-associated HIV. This novel approach targets the migration of white blood cells in semen or cervical mucus carrying HIV and offers a promising method for disease prevention.
A recent analysis of 31 studies found that individuals with HSV-2 infection are twice as likely to contract HIV, with up to half of cases attributed to preceding HSV-2 infection. The study highlights the importance of controlling HSV-2 infection in preventing HIV acquisition.
Researchers found a significant link between sarcoidosis and family history, with affected individuals more likely to have siblings or parents with the disease. Air pollution during adolescence also affects lung function growth and performance, while improved HIV treatment reduces the risk of pulmonary complications.
Researchers suggest a structured intermittent therapy approach, where patients receive daily doses of HAART for seven days, followed by seven days off the medication. This regimen has shown significant reductions in certain side effects, including cholesterol and triglyceride levels, without compromising treatment efficacy.
Researchers have developed optimized antiviral peptide vaccines that exhibit enhanced efficacy against various viral infections, including HIV and SARS-CoV-2. These improvements are attributed to the incorporation of specific amino acid sequences that enhance immune responses.
A questionnaire surveyed junior doctors in two London teaching hospitals and found that nearly all were aware of post-exposure prophylaxis (PEP) but many lacked knowledge on its use. The study highlights the need for improved education on PEP among medical professionals to prevent occupationally acquired HIV infections.
A recent study by Ohio State University researchers found that gay men tend to weigh the benefits and drawbacks of revealing their HIV status, with over half disclosing to family and 63% telling friends. The top reasons for disclosure included keeping others safe and seeking understanding.
Researchers find HIV attachment to rafts is crucial for replication, and cholesterol-lowering drugs may help disrupt this process. Depleting cholesterol from rafts using compounds significantly reduces HIV's ability to infect new cells.
Researchers at Jefferson Medical College have demonstrated in the laboratory that prostratin can stimulate two main hiding areas in patients with HIV infection who are taking HAART, leading to death of the virus from anti-viral drugs. The work shows promise for a new second-generation approach to eradicate HIV from the body.
A survey of 310 pregnant women in Zambia found that 74% prefer targeted therapy with resources available, while 60% support mass drug administration if only half the population is targeted. The results suggest that most women would prioritize access to nevirapine over testing.
A study published in The Lancet found that HIV-positive women can shed the virus in their genital tracts even when their blood levels are low, posing a risk of transmission to others. The researchers analyzed samples from 311 HIV-positive women and found that about a third had HIV-1 shedding in their genital region.
Researchers at Gladstone Institute of Virology and Immunology found that HIV's Vpr gene causes the formation of nuclear herniations, disrupting cell division. This disruption enables virus production to increase severalfold, improving HIV's ability to grow and infect new cells.
Researchers found that HHV-6 inhibits early-stage HIV variants by blocking CCR5 receptors, slowing their reproduction. The harmless herpesvirus may create favorable conditions for later-stage HIV variants that use CXCR4 receptors.
A Yale study found that HIV patients who trust their physicians are 20% more likely to adhere to their treatment regimens. Lack of social support and mistrust in peers also hinder adherence to ART.
In a phase IIa trial, TMC125 demonstrated a rapid and strong antiviral effect, reducing HIV viral loads by up to 99.9%. The study showed that 8 out of 12 patients had their viral loads reduced to less than 400 copies/ml without any rebound or drug resistance.
Researchers found that infected individuals can transmit HIV to others through a single sexual encounter, often before developing flu-like symptoms. The study emphasizes the importance of not engaging in unsafe sex and highlights the need for early intervention to prevent rapid epidemic spread.
A study finds that alcohol consumption is associated with unsafe sex among injection drug users, leading to increased HIV transmission risk. The research suggests that addressing alcohol use and disorders in this population is crucial for preventing the spread of HIV.
Local experts urge a $300 million increase in Ryan White/CARE Act funding to ensure stable medical care and treatment for newly diagnosed patients. HIV infection can be managed as a chronic disease with access to services and new anti-AIDS drugs.
The collaboration between Myriad Genetics and the University of Utah revealed that the Tsg101 protein is essential for HIV1 budding, allowing for the disruption of the virus lifecycle. This breakthrough led to the identification of potential HIV drug targets, with lead compounds developed for anti-HIV therapy.
Peptide-T, a synthetic compound, prevents HIV from entering healthy human cells by adhering to specific cellular receptors. This new mechanism of action offers an alternative to existing protease inhibitors, which can develop resistance and cause harmful side effects.
Researchers have found a possible link between viral infections and a treatable form of ALS. Six patients with HIV developed symptoms of motor neuron disease after anti-HIV treatment, suggesting that the AIDS virus can cause a variant of classic ALS.
Dr. Brian L Bray's innovative approach enables mass production of T-20, a 36-amino acid peptide blocking HIV entry. The process opens up new possibilities for peptides as therapeutics and may treat millions of Americans with HIV.
Researchers argue that the cervix is a 'hot spot' for HIV infection and that physical barrier devices like the diaphragm could increase HIV prevention. The diaphragm's ability to block fluid transport may enhance the effectiveness of microbicides in killing HIV on contact.
Researchers predict that 42% of all HIV cases will be drug-resistant by 2005, mainly due to the conversion of drug-sensitive cases during antiretroviral therapy. The study recommends four epidemic-control strategies to minimize prevalence and transmission of drug-resistant HIV.
A genetic mutation in the CCR5 gene provides protection against HIV infection, slowing the spread of AIDS in African populations. Studies suggest that this mutation may be more common in European populations due to historical epidemics.
Researchers found that bisexual and homosexual Caucasian men with one copy of the delta-32 mutation have a 70% reduced risk of HIV infection compared to those without the mutation. The study, published in the Journal of Acquired Immune Deficiency Syndromes, provides insight into resistance to HIV infection among high-risk populations.
A Kenyan study found that inconsistent refrigeration, data-entry errors, and equipment failure contribute to HIV transmission through blood transfusions. The study led to the implementation of rapid HIV test kits, laboratory training programs, and universal screening of all blood donations to improve blood safety.
Researchers discovered that HIV DNA serves as a template to produce viral proteins Nef and Tat, bringing CD4 T cells out of their resting state. Non-integrated HIV DNA contributes to disease progression, despite not producing new viruses.
Dr. Duane Grandgenett receives nearly a million dollars in grants to study ways of inhibiting HIV replication in humans. He aims to develop an HIV inhibitor targeting the integrase protein, which plays a crucial role in the virus's survival.
A study by Duke University researchers found that HIV patients value high levels of control over medical record access, leading them to choose distant clinics or withhold information. The results highlight the need for providers to prioritize patient confidentiality and provide training on record-keeping and sharing.
Researchers at The Scripps Research Institute have solved the structure of a neutralizing antibody against HIV, marking an important milestone in the development of an effective vaccine. This breakthrough demonstrates that the human immune system can produce antibodies effective against HIV and provides a template for vaccine design.
AIDS researchers urge collaboration to develop new treatments for drug-resistant HIV patients, who represent 30% of treated cases in the US. The lack of effective therapies sets the stage for a dangerous epidemic of drug-resistant HIV.
Researchers at the University of Maryland Biotechnology Institute have engineered rats to contain the genome of HIV-1, making them a valuable model for studying AIDS-related diseases. The rats develop clinical signs similar to those of AIDS in humans, including neurological abnormalities and organ damage.
A recent study found that 85% of injection drug users in Baltimore obtained some needles from street sellers, highlighting the need for improved needle exchange programs. The study suggests that individually sealed syringes could be a game-changer in reducing the transmission of blood-borne diseases.
A UC Davis study finds that syringe-exchange programs reduce HIV risk among injection drug users, with benefits seen in studies conducted in the US and internationally. The programs appear to be most effective when they are the only source of clean needles available.
A Johns Hopkins study finds that removing cholesterol from a cell's membrane can completely block HIV transmission. Researchers used microbicides containing a starchy substance that drains cholesterol, allowing for reduced or stopped HIV transmission.
HIV-infected individuals taking antiretroviral therapy experience changes in fat distribution, cholesterol, and glucose metabolism, leading to anxiety-provoking body shape changes. Dr. Kingsley's proposed definition guides diagnosis and monitoring of HIV-associated lipodystrophy syndrome.
STI rates have soared since the 1990s, with HIV infection remaining high. In contrast, the 1980s saw significant declines in HIV transmission and bacterial infections when targeted awareness campaigns were implemented, highlighting the need for new campaigns to tackle these trends.
Researchers developed an Intrakine blockade to block a specific chemokine receptor, leading to reduced inflammation and modulated immune responses in various disease models. This breakthrough could provide new therapeutic avenues for treating conditions like asthma, autoimmune diseases, and cancer.
A retrospective study of 681 HIV-positive patients found that Virco's VirtualPhenotype? and Antivirogram? resistance tests accurately predicted treatment outcomes. Patients receiving three or four active drugs experienced significant reductions in viral load and increases in CD4 cell counts.
Researchers identified a polyoxometalate (POM) molecule that inhibits HIV protease, providing a potential second line of attack against the virus. The discovery could lead to reduced spread of drug-resistant strains and delayed onset of full-blown AIDS.
A new UCSF study reveals that while combination antiretroviral therapy has improved patient outcomes, it also creates uncertainty and anxiety among healthcare providers. The researchers found that providers are struggling to make informed decisions due to a lack of resources and limited information on patient adherence.
A new study finds that providing female condoms to commercial sex workers in rural South Africa is a highly cost-effective means of preventing HIV transmission. The analysis found that 5.9 cases of HIV, 38 cases of syphilis, and 33 cases of gonorrhea would be averted per year in 1,000 female condom recipients.
HIV patients who see empathetic physicians report higher satisfaction rates, with continuity of care and medication adherence being critical factors. Patients who feel less empathetic or uninformed about the disease are more likely to be dissatisfied.
Research reveals that individuals coping with HIV/AIDS exhibit diverse information-seeking behaviors, from avoiding information to seeking out multiple sources. Understanding these complexities is crucial in developing effective treatment programs, as uncertainty can be a natural part of life for some individuals.
Research finds African Americans and others with lower education and income levels have delayed access to HAART, highlighting the need for improved healthcare services. Traditional vulnerable groups, including injection drug users and minority populations, are less likely to receive timely treatment.